{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:20:41Z","timestamp":1771870841311,"version":"3.50.1"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Career Development","award":["19CDA34660045"],"award-info":[{"award-number":["19CDA34660045"]}]},{"name":"Enduring Hearts and the American Heart Association"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Regulatory T cell (Treg)\u2013biased IL-2\/anti-IL-2 monoclonal antibody complexes (IL-2c) can preferentially deliver IL-2 to CD25+ Tregs, causing proliferation of Tregs that is potentially advantageous in transplantation. We tested the ability of IL-2c to prolong murine cardiac allograft survival. C57BL\/6 (H-2b) mice received fully major histocompatibility complex\u2013mismatched BALB\/c (H-2d) or hemi-allogeneic B6 \u00d7 BALB\/c (H-2b\/d) F1 allografts. Recipients were treated prior to transplantation with IL-2c or control. Graft survival, anti-donor T cell priming, and donor-specific antibody production were measured. High-dimensional flow cytometry and transcriptomic analyses were used to characterize IL-2c\u2013induced modulation of the alloimmune response. IL-2c treatment prolonged BALB\/c allograft survival to 14\u2009d (vs. 7 in control; P\u2009&amp;lt;\u20090.0001), and F1 allograft survival to 22\u2009d (vs. 13 in control; P\u2009=\u20090.0018). Donor-specific T cell priming and antibody production were significantly reduced by IL-2c. Increased frequencies of CD4+CD25+FOXP3+ Tregs expressing high levels of ICOS, GITR, CD73, and CTLA-4 were identified in both the spleen and allograft in IL-2c\u2013treated recipients. Reduced infiltration of F4\/80+ cells into allografts and a marked reduction in intragraft myeloid activity were observed in IL-2c\u2013treated recipients. When combined with a transient 21-d course of perioperative tacrolimus therapy, median survival time was extended to 48\u2009d, and some recipients experienced indefinite allograft survival without ongoing immunosuppressive therapy. IL-2c increases Treg populations in priming and effector sites, is associated with downregulation of both the early adaptive immune response and myeloid response to cardiac allografts, and can synergize with tacrolimus to enable long-term graft survival.<\/jats:p>","DOI":"10.1093\/jimmun\/vkaf303","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:40:52Z","timestamp":1765384852000},"source":"Crossref","is-referenced-by-count":0,"title":["IL-2 complex therapy prolongs fully MHC-mismatched murine cardiac allograft survival"],"prefix":"10.1093","volume":"215","author":[{"given":"Ikbale","family":"El-Ayachi","sequence":"first","affiliation":[{"name":"Department of Surgery, The Ohio State University Wexner Medical Center , Columbus, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael N","family":"Teodorescu","sequence":"additional","affiliation":[{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University , Columbus, OH,","place":["United States"]},{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Azar","sequence":"additional","affiliation":[{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University , Columbus, OH,","place":["United States"]},{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Keslar","sequence":"additional","affiliation":[{"name":"Department of Inflammation and Immunity, Lerner Research Institute , Cleveland, OH,","place":["United States"]},{"name":"Transplant Center, Cleveland Clinic , Cleveland, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M","family":"Pawlik","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Ohio State University Wexner Medical Center , Columbus, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Washburn","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Ohio State University Wexner Medical Center , Columbus, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L","family":"Fairchild","sequence":"additional","affiliation":[{"name":"Department of Inflammation and Immunity, Lerner Research Institute , Cleveland, OH,","place":["United States"]},{"name":"Transplant Center, Cleveland Clinic , Cleveland, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark P","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University , Columbus, OH,","place":["United States"]},{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-1042","authenticated-orcid":false,"given":"Austin D","family":"Schenk","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Ohio State University Wexner Medical Center , Columbus, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"2026022312464874100_vkaf303-B1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/MOT.0000000000000831","article-title":"Repeated kidney re-transplantation in times of organ shortage\u2014a critical review","volume":"26","author":"Assfalg","year":"2021","journal-title":"Curr Opin Organ Transplant"},{"key":"2026022312464874100_vkaf303-B2","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.3390\/jcm12237418","article-title":"Worth a double take? An in-depth review of lung retransplantation","volume":"12","author":"Dawodu","year":"2023","journal-title":"J Clin Med"},{"key":"2026022312464874100_vkaf303-B3","doi-asserted-by":"crossref","first-page":"1055466","DOI":"10.3389\/fimmu.2022.1055466","article-title":"Foxp3+ regulatory T cell therapy for tolerance in autoimmunity and solid organ transplantation","volume":"13","author":"Sanders","year":"2022","journal-title":"Front Immunol"},{"key":"2026022312464874100_vkaf303-B4","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/01.TP.0000116565.86752.6B","article-title":"Regulatory CD4+CD25+ T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome","volume":"77","author":"Meloni","year":"2004","journal-title":"Transplantation"},{"key":"2026022312464874100_vkaf303-B5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/lt.20612","article-title":"Low circulating regulatory T-cell levels after acute rejection in liver transplantation","volume":"12","author":"Demirkiran","year":"2006","journal-title":"Liver Transpl"},{"key":"2026022312464874100_vkaf303-B6","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/01.ASN.0000057540.98231.C1","article-title":"Regulatory CD25+ T cells in human kidney transplant recipients","volume":"14","author":"Salama","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2026022312464874100_vkaf303-B7","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026022312464874100_vkaf303-B8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nm.2154","article-title":"In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells","volume":"16","author":"Nadig","year":"2010","journal-title":"Nat Med"},{"key":"2026022312464874100_vkaf303-B9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2006-05-025460","article-title":"In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance","volume":"109","author":"Golshayan","year":"2007","journal-title":"Blood"},{"key":"2026022312464874100_vkaf303-B10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nm1688","article-title":"Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes","volume":"14","author":"Joffre","year":"2008","journal-title":"Nat Med"},{"key":"2026022312464874100_vkaf303-B11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am J Transplant"},{"key":"2026022312464874100_vkaf303-B12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transplant"},{"key":"2026022312464874100_vkaf303-B13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92865","article-title":"T cells expressing chimeric antigen receptor promote immune tolerance","volume":"2","author":"Pierini","year":"2017","journal-title":"JCI Insight"},{"key":"2026022312464874100_vkaf303-B14","doi-asserted-by":"crossref","first-page":"622810","DOI":"10.3389\/fimmu.2020.622810","article-title":"Treg therapies revisited: tolerance beyond deletion","volume":"11","author":"Pilat","year":"2020","journal-title":"Front Immunol"},{"key":"2026022312464874100_vkaf303-B15","doi-asserted-by":"crossref","first-page":"746889","DOI":"10.3389\/fimmu.2022.746889","article-title":"Utilization of Treg cells in solid organ transplantation","volume":"13","author":"Juneja","year":"2022","journal-title":"Front Immunol"},{"key":"2026022312464874100_vkaf303-B16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/cei\/uxac105","article-title":"IL-2-based approaches to Treg enhancement","volume":"211","author":"Harris","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"2026022312464874100_vkaf303-B17","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni1263","article-title":"A function for interleukin 2 in Foxp3-expressing regulatory T cells","volume":"6","author":"Fontenot","year":"2005","journal-title":"Nat Immunol"},{"key":"2026022312464874100_vkaf303-B18","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/ni1264","article-title":"Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling","volume":"6","author":"D\u2019Cruz","year":"2005","journal-title":"Nat Immunol"},{"key":"2026022312464874100_vkaf303-B19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1074-7613(02)00367-9","article-title":"CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2","volume":"17","author":"Malek","year":"2002","journal-title":"Immunity"},{"key":"2026022312464874100_vkaf303-B20","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.4049\/jimmunol.169.9.4850","article-title":"Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers","volume":"169","author":"Almeida","year":"2002","journal-title":"J Immunol"},{"key":"2026022312464874100_vkaf303-B21","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1126\/science.1122927","article-title":"Selective stimulation of T cell subsets with antibody-cytokine immune complexes","volume":"311","author":"Boyman","year":"2006","journal-title":"Science"},{"key":"2026022312464874100_vkaf303-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.017","article-title":"A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease","volume":"95","author":"Peterson","year":"2018","journal-title":"J Autoimmun"},{"key":"2026022312464874100_vkaf303-B23","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba5264","article-title":"An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice","volume":"5","author":"Khoryati","year":"2020","journal-title":"Sci Immunol"},{"key":"2026022312464874100_vkaf303-B24","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173107","article-title":"A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models","volume":"134","author":"Efe","year":"2024","journal-title":"J Clin Invest"},{"key":"2026022312464874100_vkaf303-B25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2014.10.002","article-title":"Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells","volume":"56","author":"Bell","year":"2015","journal-title":"J Autoimmun"},{"key":"2026022312464874100_vkaf303-B26","doi-asserted-by":"crossref","first-page":"1114802","DOI":"10.3389\/fimmu.2023.1114802","article-title":"A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in mice","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"2026022312464874100_vkaf303-B27","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1016\/j.transproceed.2012.09.032","article-title":"Impact of interleukin-2-expanded regulatory T cells in various allogeneic combinations on mouse skin graft survival","volume":"44","author":"Vokaer","year":"2012","journal-title":"Transplant Proceed"},{"key":"2026022312464874100_vkaf303-B28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1084\/jem.20082824","article-title":"In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression","volume":"206","author":"Webster","year":"2009","journal-title":"J Exp Med"},{"key":"2026022312464874100_vkaf303-B29","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41467-023-36924-z","article-title":"Biased IL-2 signals induce Foxp3-rich pulmonary lymphoid structures and facilitate long-term lung allograft acceptance in mice","volume":"14","author":"Yamada","year":"2023","journal-title":"Nat Commun"},{"key":"2026022312464874100_vkaf303-B30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/TP.0000000000001852","article-title":"Utility of IL-2 complexes in promoting the survival of murine orthotopic forelimb vascularized composite allografts","volume":"102","author":"Xu","year":"2018","journal-title":"Transplantation"},{"key":"2026022312464874100_vkaf303-B31","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1073\/pnas.0909384107","article-title":"IL-2\/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25","volume":"107","author":"Letourneau","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026022312464874100_vkaf303-B32","first-page":"733","article-title":"Heart transplantation in congenic strains of mice","volume":"5","author":"Corry","year":"1973","journal-title":"Transplant Proceed"},{"key":"2026022312464874100_vkaf303-B33","doi-asserted-by":"crossref","first-page":"311ra170","DOI":"10.1126\/scitranslmed.aac8155","article-title":"IL-2Ralpha mediates temporal regulation of IL-2 signaling and enhances immunotherapy","volume":"7","author":"Su","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026022312464874100_vkaf303-B34","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s00125-020-05200-w","article-title":"Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I\/II randomised, double-blind, placebo-controlled, dose-finding study","volume":"63","author":"Rosenzwajg","year":"2020","journal-title":"Diabetologia"},{"key":"2026022312464874100_vkaf303-B35","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"key":"2026022312464874100_vkaf303-B36","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"key":"2026022312464874100_vkaf303-B37","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2019000631","article-title":"Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children","volume":"3","author":"Whangbo","year":"2019","journal-title":"Blood Adv"},{"key":"2026022312464874100_vkaf303-B38","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1158\/1078-0432.CCR-08-0116","article-title":"Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines","volume":"14","author":"Smith","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2026022312464874100_vkaf303-B39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.23552","article-title":"High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006","volume":"113","author":"Klapper","year":"2008","journal-title":"Cancer"},{"key":"2026022312464874100_vkaf303-B40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2026022312464874100_vkaf303-B41","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.4049\/jimmunol.181.10.6942","article-title":"Suppression of murine allergic airway disease by IL-2: anti-IL-2 monoclonal antibody-induced regulatory T cells","volume":"181","author":"Wilson","year":"2008","journal-title":"J Immunol"},{"key":"2026022312464874100_vkaf303-B42","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1111\/ajt.15306","article-title":"IL-2 therapy preferentially expands adoptively transferred donor-specific Tregs improving skin allograft survival","volume":"19","author":"Ratnasothy","year":"2019","journal-title":"Am J Transplant"},{"key":"2026022312464874100_vkaf303-B43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fimmu.2017.00421","article-title":"IL-2-mediated in vivo expansion of regulatory T cells combined with CD154-CD40 co-stimulation blockade but not CTLA-4 Ig prolongs allograft survival in naive and sensitized mice","volume":"8","author":"Govender","year":"2017","journal-title":"Front Immunol"},{"key":"2026022312464874100_vkaf303-B44","doi-asserted-by":"crossref","first-page":"13508","DOI":"10.1073\/pnas.1903165116","article-title":"Treg-mediated prolonged survival of skin allografts without immunosuppression","volume":"116","author":"Pilat","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026022312464874100_vkaf303-B45","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.ekir.2023.08.037","article-title":"Costimulatory blockade and solid organ transplantation: the past, present, and future","volume":"8","author":"Kitchens","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026022312464874100_vkaf303-B46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"2026022312464874100_vkaf303-B47","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jaci.2009.02.011","article-title":"IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets","volume":"123","author":"Letourneau","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"2026022312464874100_vkaf303-B48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/HYPERTENSIONAHA.116.07084","article-title":"Increasing regulatory T cells with interleukin-2 and interleukin-2 antibody complexes attenuates lung inflammation and heart failure progression","volume":"68","author":"Wang","year":"2016","journal-title":"Hypertension"},{"key":"2026022312464874100_vkaf303-B49","doi-asserted-by":"crossref","first-page":"5763430","DOI":"10.1155\/2019\/5763430","article-title":"The evolving roles of macrophages in organ transplantation","volume":"2019","author":"Li","year":"2019","journal-title":"J Immunol Res"},{"key":"2026022312464874100_vkaf303-B50","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/ki.2008.500","article-title":"The chemokine receptors CCR2 and CX3CR1 mediate monocyte\/macrophage trafficking in kidney ischemia-reperfusion injury","volume":"74","author":"Li","year":"2008","journal-title":"Kidney Int"},{"key":"2026022312464874100_vkaf303-B51","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1038\/s41467-023-39859-7","article-title":"Transcriptional and spatial profiling of the kidney allograft unravels a central role for FcyRIII+ innate immune cells in rejection","volume":"14","author":"Lamarthee","year":"2023","journal-title":"Nat Commun"},{"key":"2026022312464874100_vkaf303-B52","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1600-6143.2007.02109.x","article-title":"Monocyte infiltration and kidney allograft dysfunction during acute rejection","volume":"8","author":"Girlanda","year":"2008","journal-title":"Am J Transplant"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/215\/2\/vkaf303\/65830326\/vkaf303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/215\/2\/vkaf303\/65830326\/vkaf303.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:47:00Z","timestamp":1771868820000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/doi\/10.1093\/jimmun\/vkaf303\/8376659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jimmun\/vkaf303","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,10]]},"article-number":"vkaf303"}}